Seres Therapeutics, Inc. (NASDAQ:MCRB) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.

According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Several other research analysts have also recently weighed in on MCRB. Canaccord Genuity set a $20.00 price target on shares of Seres Therapeutics and gave the stock a “buy” rating in a report on Thursday, May 4th. Cantor Fitzgerald set a $16.00 price target on shares of Seres Therapeutics and gave the stock a “buy” rating in a report on Thursday, May 4th. Cowen and Company reaffirmed a “buy” rating on shares of Seres Therapeutics in a report on Friday, May 19th. BidaskClub raised shares of Seres Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, ValuEngine raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $16.17.

Seres Therapeutics (NASDAQ:MCRB) opened at 13.69 on Tuesday. Seres Therapeutics has a 52 week low of $8.85 and a 52 week high of $15.09. The stock has a 50 day moving average price of $11.94 and a 200 day moving average price of $10.51. The company’s market cap is $552.94 million.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.59) by $0.10. The firm had revenue of $3 million during the quarter, compared to the consensus estimate of $3 million. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The company’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.70) EPS. On average, equities analysts forecast that Seres Therapeutics will post ($2.53) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/08/08/seres-therapeutics-inc-nasdaqmcrb-stock-rating-lowered-by-zacks-investment-research.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MCRB. Vanguard Group Inc. boosted its position in Seres Therapeutics by 7.1% in the first quarter. Vanguard Group Inc. now owns 1,565,663 shares of the biotechnology company’s stock worth $17,645,000 after buying an additional 103,456 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Seres Therapeutics by 15.9% in the first quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock worth $4,172,000 after buying an additional 50,860 shares in the last quarter. State Street Corp boosted its position in Seres Therapeutics by 6.4% in the fourth quarter. State Street Corp now owns 275,970 shares of the biotechnology company’s stock worth $2,733,000 after buying an additional 16,671 shares in the last quarter. Geode Capital Management LLC boosted its position in Seres Therapeutics by 5.8% in the first quarter. Geode Capital Management LLC now owns 166,325 shares of the biotechnology company’s stock worth $1,874,000 after buying an additional 9,060 shares in the last quarter. Finally, TIAA CREF Investment Management LLC boosted its position in Seres Therapeutics by 14.4% in the first quarter. TIAA CREF Investment Management LLC now owns 110,076 shares of the biotechnology company’s stock worth $1,241,000 after buying an additional 13,825 shares in the last quarter. 75.31% of the stock is currently owned by institutional investors and hedge funds.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.